Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalSBMFF +15.29%61 Earnings Yield (Joel Greenblatt) % is 6.90% as of Dec. 2025, which is 12% below its 10-year median of 7.80. GuruFocus rates SBMFF with a GF Score™ of 61/100 and a GF Value™ of $0.70 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,344 Biotechnology companies, Sino Biopharmaceutical ranks better than 94.64% on this metric.
Sino Biopharmaceutical's Enterprise Value for the quarter that ended in Dec. 2025 was $16,246 Mil.
Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $1,269 Mil. Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 6.90%.
The historical rank and industry rank for Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SBMFF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.52 Med: 7.8 Max: 30.52
Current: 9.61
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Sino Biopharmaceutical was 30.52%. The lowest was 3.52%. And the median was 7.80%.
SBMFF's Earnings Yield (Joel Greenblatt) % is ranked better than 94.64% of 1344
companies
in the Biotechnology industry
Industry Median: -10.02
vs SBMFF: 9.61
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sino Biopharmaceutical's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was -2.49%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sino Biopharmaceutical (OTCPK:SBMFF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sino Biopharmaceutical Earnings Yield (Joel Greenblatt) % Related Terms
Sino Biopharmaceutical Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % falls into.
Sino Biopharmaceutical Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sino Biopharmaceuticals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 6.90% mean?
Sino Biopharmaceutical (SBMFF) has a Earnings Yield (Joel Greenblatt) % of 6.90% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sino Biopharmaceutical and its competitors. This is 12% below median its historical median of 7.80. Over the past decade, Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % has ranged from 3.52 to 30.52. According to the industry distribution chart, Sino Biopharmaceutical ranks #72 out of 1344 companies in the Biotechnology industry, placing it in the top 5.4%.
Is Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % too high?
Sino Biopharmaceutical's current Earnings Yield (Joel Greenblatt) % of 6.90% is 12% below median its 10-year median of 7.80. Over the past 10 years, this metric has ranged from a low of 3.52 to a high of 30.52. Based on the distribution chart, Sino Biopharmaceutical ranks #72 out of 1344 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sino Biopharmaceutical has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #72 out of 1344 companies for Earnings Yield (Joel Greenblatt) %. This places Sino Biopharmaceutical in the top 5% of its industry — outperforming the majority of peers. Historically, Sino Biopharmaceutical's own Earnings Yield (Joel Greenblatt) % has ranged from 3.52 to 30.52 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Earnings Yield (Joel Greenblatt) % is 6.90%, which is 12% below median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Fairly Valued. The stock's GF Value™ is $0.70, compared to a current price of $0.75 — trading 7.2% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 6.90%, which is 12% below median its 10-year median of 7.80. Sino Biopharmaceutical's overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Earnings Yield (Joel Greenblatt) % is 6.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of $0.75 is trading 7.2% above its estimated GF Value™ of $0.70.
GuruFocus considers Sino Biopharmaceutical to be Fairly Valued.
Key valuation signals for SBMFF:
Earnings Yield (Joel Greenblatt) %: 6.90% (12% below median its 10-year median of 7.80)
GF Value™: $0.70 vs. price of $0.75 (7.2% above fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
61GF Score
Get the complete analysis for SBMFF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
